First Time Loading...

23andMe Holding Co.
NASDAQ:ME

Watchlist Manager
23andMe Holding Co. Logo
23andMe Holding Co.
NASDAQ:ME
Watchlist
Price: 0.4671 USD -5.39% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

ME's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. [ Read More ]

The intrinsic value of one ME stock under the Base Case scenario is 2.4192 USD. Compared to the current market price of 0.4671 USD, 23andMe Holding Co. is Undervalued by 81%.

Key Points:
ME Intrinsic Value
Base Case
2.4192 USD
Undervaluation 81%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
23andMe Holding Co.

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ME stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
23andMe Holding Co.

Provide an overview of the primary business activities
of 23andMe Holding Co..

What unique competitive advantages
does 23andMe Holding Co. hold over its rivals?

What risks and challenges
does 23andMe Holding Co. face in the near future?

Has there been any significant insider trading activity
in 23andMe Holding Co. recently?

Summarize the latest earnings call
of 23andMe Holding Co..

What significant events have occurred
in 23andMe Holding Co. over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for 23andMe Holding Co..

Provide P/S
for 23andMe Holding Co..

Provide P/E
for 23andMe Holding Co..

Provide P/OCF
for 23andMe Holding Co..

Provide P/FCFE
for 23andMe Holding Co..

Provide P/B
for 23andMe Holding Co..

Provide EV/S
for 23andMe Holding Co..

Provide EV/GP
for 23andMe Holding Co..

Provide EV/EBITDA
for 23andMe Holding Co..

Provide EV/EBIT
for 23andMe Holding Co..

Provide EV/OCF
for 23andMe Holding Co..

Provide EV/FCFF
for 23andMe Holding Co..

Provide EV/IC
for 23andMe Holding Co..

Show me price targets
for 23andMe Holding Co. made by professional analysts.

What are the Revenue projections
for 23andMe Holding Co.?

How accurate were the past Revenue estimates
for 23andMe Holding Co.?

What are the Net Income projections
for 23andMe Holding Co.?

How accurate were the past Net Income estimates
for 23andMe Holding Co.?

What are the EPS projections
for 23andMe Holding Co.?

How accurate were the past EPS estimates
for 23andMe Holding Co.?

What are the EBIT projections
for 23andMe Holding Co.?

How accurate were the past EBIT estimates
for 23andMe Holding Co.?

Compare the revenue forecasts
for 23andMe Holding Co. with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of 23andMe Holding Co. and its key competitors using the latest financial data.

Compare historical revenue growth rates
of 23andMe Holding Co. against its competitors.

Analyze the profit margins
(gross, operating, and net) of 23andMe Holding Co. compared to its peers.

Compare the P/E ratios
of 23andMe Holding Co. against its peers.

Discuss the investment returns and shareholder value creation
comparing 23andMe Holding Co. with its peers.

Analyze the financial leverage
of 23andMe Holding Co. compared to its main competitors.

Show all profitability ratios
for 23andMe Holding Co..

Provide ROE
for 23andMe Holding Co..

Provide ROA
for 23andMe Holding Co..

Provide ROIC
for 23andMe Holding Co..

Provide ROCE
for 23andMe Holding Co..

Provide Gross Margin
for 23andMe Holding Co..

Provide Operating Margin
for 23andMe Holding Co..

Provide Net Margin
for 23andMe Holding Co..

Provide FCF Margin
for 23andMe Holding Co..

Show all solvency ratios
for 23andMe Holding Co..

Provide D/E Ratio
for 23andMe Holding Co..

Provide D/A Ratio
for 23andMe Holding Co..

Provide Interest Coverage Ratio
for 23andMe Holding Co..

Provide Altman Z-Score Ratio
for 23andMe Holding Co..

Provide Quick Ratio
for 23andMe Holding Co..

Provide Current Ratio
for 23andMe Holding Co..

Provide Cash Ratio
for 23andMe Holding Co..

What is the historical Revenue growth
over the last 5 years for 23andMe Holding Co.?

What is the historical Net Income growth
over the last 5 years for 23andMe Holding Co.?

What is the current Free Cash Flow
of 23andMe Holding Co.?

Discuss the annual earnings per share (EPS)
trend over the past five years for 23andMe Holding Co..

Financials

Balance Sheet Decomposition
23andMe Holding Co.

Current Assets 298m
Cash & Short-Term Investments 256.4m
Receivables 1.5m
Other Current Assets 40.1m
Non-Current Assets 503.2m
PP&E 85.4m
Intangibles 408.5m
Other Non-Current Assets 9.3m
Current Liabilities 101.6m
Accounts Payable 8.5m
Accrued Liabilities 51.9m
Other Current Liabilities 41.2m
Non-Current Liabilities 74.4m
Other Non-Current Liabilities 74.4m
Efficiency

Earnings Waterfall
23andMe Holding Co.

Revenue
248m USD
Cost of Revenue
-135.7m USD
Gross Profit
112.3m USD
Operating Expenses
-444m USD
Operating Income
-331.7m USD
Other Expenses
-190.3m USD
Net Income
-522m USD

Free Cash Flow Analysis
23andMe Holding Co.

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ME Profitability Score
Profitability Due Diligence

23andMe Holding Co.'s profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative Operating Income
21/100
Profitability
Score

23andMe Holding Co.'s profitability score is 21/100. The higher the profitability score, the more profitable the company is.

ME Solvency Score
Solvency Due Diligence

23andMe Holding Co.'s solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

23andMe Holding Co.'s solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ME Price Targets Summary
23andMe Holding Co.

Wall Street analysts forecast ME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ME is 1.2597 USD with a low forecast of 0.4747 USD and a high forecast of 2.1 USD.

Lowest
Price Target
0.4747 USD
2% Upside
Average
Price Target
1.2597 USD
170% Upside
Highest
Price Target
2.1 USD
350% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ME Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ME Price
23andMe Holding Co.

1M 1M
+4%
6M 6M
-39%
1Y 1Y
-76%
3Y 3Y
-95%
5Y 5Y
-95%
10Y 10Y
-95%
Annual Price Range
0.4671
52w Low
0.3562
52w High
2.16
Price Metrics
Average Annual Return -31%
Standard Deviation of Annual Returns 42.21%
Max Drawdown -98%
Shares Statistics
Market Capitalization 223.6m USD
Shares Outstanding 482 920 000
Percentage of Shares Shorted 10.85%

ME Return Decomposition
Main factors of price return

What is price return decomposition?

ME News

Other Videos

Last Important Events
23andMe Holding Co.

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
23andMe Holding Co.

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

23andMe Holding Co. Logo
23andMe Holding Co.

Country

United States of America

Industry

Health Care

Market Cap

223.6m USD

Dividend Yield

0%

Description

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

Contact

CALIFORNIA
South San Francisco
349 Oyster Point Boulevard
+16509386300.0
https://investors.23andme.com/

IPO

2020-10-06

Employees

-

Officers

Co-Founder, CEO, President & Chair of the Board
Ms. Anne Wojcicki
Interim CFO & Accounting Officer
Mr. Joseph Selsavage
Chief Administrative Officer & Corporate Secretary
Ms. Kathy L. Hibbs Esq., J.D.
Vice President & Interim General Counsel
Mr. Guy Chayoun
Vice President of Communications
Ms. Katie Watson
Chief Marketing Officer
Mr. Jonathan Ward
Show More
Chief Corporate Development Officer
Mr. Reza Afkhami M.B.A.
Vice President of People
Ms. Savita Pillai
Head of Therapeutics Development
Dr. Jennifer Low
Vice President of Consumer Operations
Mr. Kent Hillyer
Show Less

See Also

Discover More
What is the Intrinsic Value of one ME stock?

The intrinsic value of one ME stock under the Base Case scenario is 2.4192 USD.

Is ME stock undervalued or overvalued?

Compared to the current market price of 0.4671 USD, 23andMe Holding Co. is Undervalued by 81%.